EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(3), P. 492 - 542

Published: June 7, 2024

Language: Английский

---

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Journal of Obesity & Metabolic Syndrome, Journal Year: 2023, Volume and Issue: 32(3), P. 197 - 213

Published: Sept. 13, 2023

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for associated with metabolic syndrome. MASLD most common cause of chronic and leading liver-related morbidity mortality. It important that all stakeholders be involved in tackling public health threat obesity obesity-related diseases, including MASLD. A simple clear assessment referral pathway using non-invasive tests essential to ensure patients severe are identified referred specialist care, while less remain primary where they best managed. While lifestyle intervention cornerstone management MASLD, cardiovascular risk must properly assessed managed because No pharmacological agent has been approved treatment but novel anti-hyperglycemic drugs appear have benefit. Medications used diabetes other conditions may need adjusted as progresses cirrhosis, especially decompensated cirrhosis. Based on tests, concepts compensated advanced clinically significant portal hypertension provide a practical approach stratifying according complications can help manage such patients. Finally, prevention sarcopenia should considered

Language: Английский

---

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Obesity Facts, Journal Year: 2024, Volume and Issue: 17(4), P. 374 - 444

Published: Jan. 1, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty (NAFLD), is defined as (SLD) in the presence of one or more cardiometabolic risk factor(s) and absence harmful alcohol intake. The spectrum MASLD includes steatosis, metabolic steatohepatitis (MASH, NASH), fibrosis, cirrhosis MASH-related hepatocellular carcinoma (HCC). This joint EASL-EASD-EASO guideline provides an update on definitions, prevention, screening, diagnosis treatment for MASLD. Case-finding strategies with using non-invasive tests, should be applied individuals factors, abnormal enzymes, and/or radiological signs hepatic particularly type 2 diabetes (T2D) obesity additional factor(s). A stepwise approach blood-based scores (such FIB-4) and, sequentially, imaging techniques transient elastography) suitable to rule-out/in advanced which predictive liver-related outcomes. In adults MASLD, lifestyle modification - including weight loss, dietary changes, physical exercise discouraging consumption well optimal management comorbidities use incretin-based therapies (e.g. semaglutide, tirzepatide) T2D obesity, if indicated advised. Bariatric surgery also option obesity. If locally approved dependent label, non-cirrhotic MASH significant fibrosis (stage ≥2) considered a MASH-targeted resmetirom, demonstrated histological effectiveness acceptable safety tolerability profile. No pharmacotherapy can currently recommended cirrhotic stage. Management adaptations drugs, nutritional counselling, surveillance portal hypertension HCC, transplantation decompensated cirrhosis.

Language: Английский

---

Metabolic syndrome

Nature Reviews Disease Primers, Journal Year: 2024, Volume and Issue: 10(1)

Published: Oct. 17, 2024

Language: Английский

---

2023 Obesity Fact Sheet: Prevalence of Obesity and Abdominal Obesity in Adults, Adolescents, and Children in Korea from 2012 to 2021

Journal of Obesity & Metabolic Syndrome, Journal Year: 2024, Volume and Issue: 33(1), P. 27 - 35

Published: March 27, 2024

The 2023 Obesity Fact Sheet aims to present an updated overview of obesity prevalence across all age groups, including children and adolescents.

Language: Английский

---

Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study

Metabolism, Journal Year: 2024, Volume and Issue: 152, P. 155789 - 155789

Published: Jan. 13, 2024

Language: Английский

---

Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

The Lancet, Journal Year: 2025, Volume and Issue: 405(10481), P. 813 - 838

Published: March 1, 2025

Overweight and obesity is a global epidemic. Forecasting future trajectories of the epidemic crucial for providing an evidence base policy change. In this study, we examine historical trends global, regional, national prevalence adult overweight from 1990 to 2021 forecast 2050. Leveraging established methodology Global Burden Diseases, Injuries, Risk Factors Study, estimated among individuals aged 25 years older by age sex 204 countries territories Retrospective current were derived based on both self-reported measured anthropometric data extracted 1350 unique sources, which include survey microdata reports, as well published literature. Specific adjustment was applied correct self-report bias. Spatiotemporal Gaussian process regression models used synthesise data, leveraging spatial temporal correlation in epidemiological trends, optimise comparability results across time geographies. To generate estimates, forecasts Socio-demographic Index patterns presented annualised rate change inform trajectories. We considered reference scenario assuming continuation trends. Rates increased at regional levels, all nations, between 2021. 2021, 1·00 billion (95% uncertainty interval [UI] 0·989-1·01) males 1·11 (1·10-1·12) females had obesity. China largest population adults with (402 million [397-407] individuals), followed India (180 [167-194]) USA (172 [169-174]). The highest age-standardised observed Oceania north Africa Middle East, many these reporting more than 80% adults. Compared 1990, 155·1% (149·8-160·3) 104·9% UI 100·9-108·8) females. most rapid rise East super-region, where rates tripled doubled. Assuming 2050, that total number living will reach 3·80 3·39-4·04), over half likely time. While China, India, continue constitute large proportion obesity, sub-Saharan super-region forecasted increase 254·8% (234·4-269·5). Nigeria specifically, 141 (121-162) making it country fourth-largest No date has successfully curbed rising Without immediate effective intervention, globally. Particularly Asia Africa, driven growing populations, substantially. These regions face considerable obesity-related disease burden. Merely acknowledging health issue would be negligent part public practitioners; aggressive targeted measures are required address crisis, one foremost avertible risks now poses unparalleled threat premature death local, national, levels. Bill & Melinda Gates Foundation.

Language: Английский

---

Diabetes Fact Sheets in Korea 2024

Diabetes & Metabolism Journal, Journal Year: 2025, Volume and Issue: 49(1), P. 24 - 33

Published: Jan. 1, 2025

This study aimed to investigate the prevalence, management, and comorbidities of diabetes mellitus among Korean adults. Data from Korea National Health Nutrition Examination Survey (2019-2022) were analyzed assess treatment, risk factors, diabetes. Comparisons between young older adults with emphasized. Among aged ≥30 years, prevalence is 15.5% during 2021-2022. Of these, 74.7% aware their condition, 70.9% received antidiabetic only 32.4% achieved glycosylated hemoglobin (HbA1c) <6.5%. Moreover, 15.9% met integrated management targets, which included HbA1c <6.5%, blood pressure <140/85 mm Hg, low-density lipoprotein cholesterol <100 mg/dL. In 19 39 was 2.2%. them, 43.3% 34.6% 29.6% Obesity affected 87.1%, 26.9% had both hypertension hypercholesterolemia. ≥65 29.3%, awareness, control rates 78.8%, 75.7%, 31.2%, respectively. Integrated targets (HbA1c <7.5%, hypertension, lipids) by 40.1%. Diabetes remains highly prevalent adults, significant gaps in glycemic, pressure, lipid control. Older show higher awareness treatment but limited outcomes. Young bear a burden obesity comorbidities, alongside low rates. Therefore, early intervention programs, education, strategies tailored younger populations are urgently required.

Language: Английский

---

Influence of metabolic state and body composition on the action of pharmacological treatment of migraine

The Journal of Headache and Pain, Journal Year: 2024, Volume and Issue: 25(1)

Published: Feb. 12, 2024

Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in fertile years, and women. impacts quality life affected individuals tremendously and, addition, it associated highly prevalent metabolic diseases, such as obesity, diabetes mellitus thyroid dysfunction. Also, clinical response to drugs might be patients disease due body composition change. Therefore, efficacy antimigraine could altered both migraine disease. However, knowledge pharmacology related effects are limited. given relevance, this article provides comprehensive overview current research hypotheses influence state on action drugs. In functioning vice versa, diseases its hormonal modulating medication activity outlined. Future exploration personalizing treatment individual characteristics necessary enhance therapeutic strategies, especially increasing significance recent decades.

Language: Английский

---

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Clinical and Molecular Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 9, 2025

Background/Aims: Direct-acting antivirals (DAAs) effectively eradicate hepatitis C virus (HCV).This study investigated whether metabolic dysfunction influences the likelihood of fibrosis regression after DAA treatment in patients with chronic (CHC).Methods: This multicenter, retrospective included 8,819 diagnosed CHC who were treated DAAs and achieved a sustained virological response (SVR) between January 2014 December 2022.Fibrosis was defined as 20% reduction noninvasive surrogates for liver fibrosis, such stiffness (LS) measured by vibrationcontrolled transient elastography (VCTE) fibrosis-4 (FIB-4) score.Hypercholesterolemia (h-TC) >200 mg/dL. Results:The median age population 59.6 years, predominance male (n = 4,713, 57.3%).Genotypes 1, 2, others confirmed 3,872 (46.2%), 3,487 (41.6%), 1,024 (12.2%) patients, respectively.Diabetes mellitus (DM) present 1,442 (17.2%) LS 7.50 kPa (interquartile range, 5.30-12.50).Multivariate analysis revealed that presence DM pre-DAA h-TC independently associated decreased probability VCTE Additionally, FIB-4. Conclusions: Metabolic has an unfavorable influence on inpatients achieve SVR treatment.

Language: Английский

---